Sarcopenia prevalence and its clinical impact are reportedly variable in chronic obstructive
pulmonary disease (COPD) due partly to definition criteria. This review aimed to identify the …

COPD is associated with a progressive loss of muscle mass and function. However, there is
an unmet need to define and standardise methods to estimate the prevalence of sarcopenia …

Chronic obstructive pulmonary disease (COPD) has been described as a systemic disease.
Sarcopenia is one of the systemic effects that is related to several adverse outcomes. The …

Background Age-related loss of muscle, sarcopenia, is recognised as a clinical syndrome
with multiple contributing factors. International European Working Group on Sarcopenia in …

Background Muscle wasting and chronic inflammation are predominant features of patients
with COPD. Systemic inflammation is associated with an accelerated decline in lung …

The awareness of the presence and consequences of sarcopenia has significantly
increased over the past decade. Sarcopenia is defined as gradual loss of muscle mass and …

Abstract Introduction recently, the European Working Group on Sarcopenia in Older People
(EWGSOP) established a new operational definition and cut-off points for sarcopenia. The …

Decreased physical performance due to loss of muscle mass (ie sarcopenia) is prevalent in
ageing and appears more pronounced in chronic disease. A comprehensive profile of the …

Objective: To evaluate the prevalence of sarcopenia in COPD patients, as well as to
determine whether sarcopenia correlates with the severity and prognosis of COPD …

Abstract Background/Objectives Sarcopenia defined by the association of skeletal muscle
mass depletion and a decreased physical performance is underdiagnosed in chronic …